These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 36154176)
101. Dual and triple modulator therapy for chronic rhinosinusitis in cystic fibrosis patients. Uyttebroek S; Claeyssens C; Jorissen M; Dupont L; Van Gerven L Rhinology; 2024 Mar; ():. PubMed ID: 38530204 [TBL] [Abstract][Full Text] [Related]
102. Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis. FitzMaurice TS; Nazareth D; Iyer K; Walshaw M; Al-Aloul M Exp Clin Transplant; 2022 Apr; 20(4):433-435. PubMed ID: 35297329 [TBL] [Abstract][Full Text] [Related]
104. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor. Becq F; Mirval S; Carrez T; Lévêque M; Billet A; Coraux C; Sage E; Cantereau A Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34266939 [TBL] [Abstract][Full Text] [Related]
105. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344 [TBL] [Abstract][Full Text] [Related]
106. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events. Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736 [TBL] [Abstract][Full Text] [Related]
108. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy. Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA Respir Res; 2023 Dec; 24(1):317. PubMed ID: 38104128 [TBL] [Abstract][Full Text] [Related]
109. Safety and effectiveness of treatment with elexacaftor, tezacaftor and ivacaftor in adults with cystic fibrosis. Nieto Royo R; Durán Barata D; Barrios Barreto D; Briceño Franquiz W; Máiz Carro L Med Clin (Barc); 2023 Oct; 161(8):338-341. PubMed ID: 37474394 [TBL] [Abstract][Full Text] [Related]
110. The Cystic Fibrosis Upper and Lower Airway Metagenome. Pienkowska K; Pust MM; Gessner M; Gaedcke S; Thavarasa A; Rosenboom I; Morán Losada P; Minso R; Arnold C; Hedtfeld S; Dorda M; Wiehlmann L; Mainz JG; Klockgether J; Tümmler B Microbiol Spectr; 2023 Mar; 11(2):e0363322. PubMed ID: 36892308 [TBL] [Abstract][Full Text] [Related]
111. Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy. Cimino G; Sorrenti S; Murciano M; Galoppi P; Ascenzioni F; Botta B; Brunelli R; Arch Gynecol Obstet; 2024 Jan; 309(1):9-15. PubMed ID: 36907900 [TBL] [Abstract][Full Text] [Related]
112. Use of CFTR modulators in special populations, part 3: Solid organ transplant. Kadouh NK; Elijah J; Fitzgerald LJ; Phan H Pediatr Pulmonol; 2023 Dec; 58(12):3393-3402. PubMed ID: 37067449 [TBL] [Abstract][Full Text] [Related]
113. Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis. Xu W; Wu T; Zhou Z; Zuo Z Front Pharmacol; 2023; 14():1275470. PubMed ID: 38186649 [No Abstract] [Full Text] [Related]
114. Unplanned pregnancies following the introduction of elexacaftor/tezacaftor/ivacaftor therapy in women with cystic fibrosis. Daccò V; Alicandro G; Trespidi L; Gramegna A; Blasi FA Arch Gynecol Obstet; 2023 Nov; 308(5):1657-1659. PubMed ID: 37517074 [TBL] [Abstract][Full Text] [Related]
115. Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis. Gramegna A; Majo F; Alicandro G; Leonardi G; Cristiani L; Amati F; Contarini M; Aliberti S; Fiocchi AG; Blasi F Respir Res; 2023 Jun; 24(1):164. PubMed ID: 37330504 [TBL] [Abstract][Full Text] [Related]
116. The impact of elexacaftor/tezacaftor/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: An expert-based Delphi consensus. Gramegna A; Aliberti S; Calderazzo MA; Casciaro R; Ceruti C; Cimino G; Fabrizzi B; Lucanto C; Messore B; Pisi G; Taccetti G; Tarsia P; Blasi F; Cipolli M Respir Med; 2023 Dec; 220():107455. PubMed ID: 37926181 [TBL] [Abstract][Full Text] [Related]
117. Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy. Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA Res Sq; 2023 Sep; ():. PubMed ID: 37841851 [TBL] [Abstract][Full Text] [Related]
118. Enhanced CFTR modulator efficacy in ΔF508 CFTR mouse organoids by ablation of RFFL ubiquitin ligase. Hinata D; Fukuda R; Ishiguro H; Kamada Y; Okiyoneda T Biochem Biophys Res Commun; 2024 Jul; 733():150433. PubMed ID: 39047427 [TBL] [Abstract][Full Text] [Related]